Evotec SE ADR (EVO) - Total Liabilities
Based on the latest financial reports, Evotec SE ADR (EVO) has total liabilities worth $972.56 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore EVO operating cash flow to assess how effectively this company generates cash.
Evotec SE ADR - Total Liabilities Trend (2003–2024)
This chart illustrates how Evotec SE ADR's total liabilities have evolved over time, based on quarterly financial data. Check Evotec SE ADR liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Evotec SE ADR Competitors by Total Liabilities
The table below lists competitors of Evotec SE ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Union Holdings Ltd
SHE:000036
|
China | CN¥1.69 Billion |
|
Olema Pharmaceuticals Inc
NASDAQ:OLMA
|
USA | $44.97 Million |
|
Isras Investment Company Ltd
TA:ISRS
|
Israel | ILA5.36 Billion |
|
Energy Resources of Australia Ltd
AU:ERA
|
Australia | AU$2.41 Billion |
|
Arcos Dorados Holdings Inc
NYSE:ARCO
|
USA | $2.82 Billion |
|
Fujian Septwolves Industry Co Ltd
SHE:002029
|
China | CN¥3.25 Billion |
|
Teladoc Inc
NYSE:TDOC
|
USA | $1.49 Billion |
|
Shanghai Zhezhong Construction Co Ltd
SHE:002346
|
China | CN¥1.14 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Evotec SE ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EVO company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evotec SE ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evotec SE ADR (2003–2024)
The table below shows the annual total liabilities of Evotec SE ADR from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $959.98 Million | -18.59% |
| 2023-12-31 | $1.18 Billion | +10.19% |
| 2022-12-31 | $1.07 Billion | +24.79% |
| 2021-12-31 | $857.48 Million | -9.86% |
| 2020-12-31 | $951.26 Million | +12.66% |
| 2019-12-31 | $844.39 Million | +143.34% |
| 2018-12-31 | $347.00 Million | +3.42% |
| 2017-12-31 | $335.52 Million | +144.14% |
| 2016-12-31 | $137.43 Million | +35.47% |
| 2015-12-31 | $101.44 Million | +53.20% |
| 2014-12-31 | $66.22 Million | -3.21% |
| 2013-12-31 | $68.41 Million | -6.13% |
| 2012-12-31 | $72.88 Million | +2.69% |
| 2011-12-31 | $70.97 Million | +19.83% |
| 2010-12-31 | $59.22 Million | +68.67% |
| 2009-12-31 | $35.11 Million | +6.27% |
| 2008-12-31 | $33.04 Million | -11.48% |
| 2007-12-31 | $37.33 Million | -45.39% |
| 2006-12-31 | $68.35 Million | +82.55% |
| 2005-12-31 | $37.44 Million | +307.75% |
| 2004-12-31 | $9.18 Million | +61.18% |
| 2003-12-31 | $5.70 Million | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more